Ordering semaglutide from India through an overseas website is not a lawful shortcut to an authorized U.S. medicine. A drug cleared for sale in India does not automatically hold authorization for sale to U.S. patients.
As of October 17, 2026, the day this article was written, the FDA had published two warning letters about Indian-brand semaglutide. Both letters posted on October 6, 2026. Regulators had reviewed two websites offering Semanat and Semanext to U.S. buyers.
Here is what those warnings say and how a U.S. prescription differs.
Why Semaglutide from India Drew October 2026 FDA Warning Letters
FDA staff reviewed the two sites on August 26 and September 2, 2026. The agency issued warning letters later that month, and both pages went live on October 6, 2026.
The September 23, 2026 warning letter to Online Generic Medicine cited offers of Semanat Injection (Semaglutide) to U.S. buyers. Its FDA record lists a United States recipient country. It also documents sales made "without requiring a prescription" on the site.
The September 24, 2026 warning letter to Cheap Medicine Shop cited offers of Semanext Injection. That letter lists India as the recipient country. Only the Online Generic Medicine letter documented no-prescription sales as a separate finding.
Both letters state that "there are no approved drug applications pursuant to section 505 of the FD&C Act in effect" for these drugs. Both also state that U.S.-authorized semaglutide is "only available pursuant to a prescription from a licensed practitioner" in the United States. Unsafe injectables also risk "serious and life-threatening conditions such as septicemia or sepsis," a severe bloodstream infection.
Both brands appear in March 2026 company announcements from India. In its March 20 filing, NATCO reported February Indian clearance and a planned March 21 launch of SEMANAT and SEMAFULL for adult type 2 diabetes.
Lupin agreed to "co-market Zydus’ innovative Semaglutide Injection in India under the brand names Semanext® and Lupin’s Livarise®" in its March 17, 2026 release. The FDA letters fault the two online sellers. They do not accuse NATCO, Lupin, or Zydus of those violations.
What Buying Indian Generic Semaglutide Online Actually Means
A real Indian brand name on a website does not verify what will arrive at a U.S. address. U.S. authorization applies to a specific finished drug distributed through an authorized supply chain.
Under FDA's personal-importation policy, updated August 18, 2025, importing foreign drugs for personal use is unlawful in most circumstances. A prescription alone is not a routine exemption.
FDA staff "may consider" narrow discretion only for a serious condition without effective U.S. treatment. The criteria include no U.S. promotion, no unreasonable risk, written confirmation of personal use, and generally no more than three months’ supply. Patients also need either U.S.-doctor contact details or evidence of continuing treatment begun abroad.
We cover U.S. patent rules in generic semaglutide and cross-border shipping rules in buying semaglutide from Canada. Two published studies show why the supply chain matters as much as the ingredient name.
In a 2024 JAMA Network Open investigation, Amir Reza Ashraf and colleagues ordered semaglutide from six no-prescription websites. Only three orders arrived, and the other three were non-delivery scams. "The measured semaglutide content substantially exceeded the labeled amount in each sample by 29% to 39%," the authors reported.
That means a standard draw would deliver roughly a third more medicine than labeled. One vial also had elevated endotoxin; the study tested product quality rather than patient reactions. No live microbes grew in the samples.
By contrast, a May 2026 phase 3 trial in Metabolism Open by Prabhat Kumar Sharma and colleagues tested a Zydus formulation. The 24-week Indian trial enrolled 314 adults with type 2 diabetes on metformin, with 274 completing follow-up. The between-group difference in 24-week reduction of HbA1c, a measure of average blood sugar, was "−0.0038 percentage points (95% CI –0.20 to 0.19; p = 0.97)."
The trial met its prespecified non-inferiority margin for blood-sugar control. Still, one Zydus-funded trial cannot verify an unrelated website's parcel.
| Study | Design and sample | Key finding | Limit for U.S. buyers |
|---|---|---|---|
| Ashraf et al., JAMA Network Open (2024) | 6 orders from no-prescription sites; 3 vials arrived | Semaglutide exceeded label by 29% to 39%; 1 vial had high endotoxin | Tiny sample; did not test Semanat, Semanext, or 2026 sellers |
| Sharma et al., Metabolism Open (2026) | 24-week trial in 314 Indian adults with diabetes (157 per arm) | Met the trial’s limit on how much worse blood-sugar control could be: 0.4 percentage points in HbA1c, a measure of average blood sugar; adverse events 58.6% vs 61.8%, none serious | Zydus-funded trial of one drug; cannot verify online parcels or Promise products |
Patients exploring U.S. prescription options sometimes discuss other molecules with a clinician, such as tirzepatide. "Tirzepatide is a GIP receptor and GLP-1 receptor agonist," according to the August 2026 Mounjaro prescribing information. It acts on two gut-hormone receptors instead of one, making it a separate prescription option rather than generic semaglutide.
What the Warning Letters Do Not Mean
The September 2026 letters are website-review warnings, not factory inspection reports. They do not prohibit Indian drug manufacturing or recall every semaglutide product made in India.
The letters also do not report lab tests showing that Semanat or Semanext caused actual sepsis cases or deaths. Instead, the FDA's infection language explains the conditional risk of injecting unvetted products sold outside U.S. oversight.
Finally, these letters address foreign finished generics, not U.S. patient-specific compounding covered in compounded semaglutide. Semaglutide or tirzepatide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy. Each is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.
An October 2026 FDA alert on unapproved GLP-1 drugs notes that "compounded drugs are not FDA approved" and receive no premarket review. Patient-specific medical-need rules still govern compounding. A licensed provider may still prescribe — that decision is between you and your doctor.
How a Prescribed U.S. Route Differs from an Unverified Seller
The real difference is between an unverified box and a traceable clinical chain. We detail that process in how to get semaglutide prescribed.
The May 2026 Ozempic prescribing information defines semaglutide as a GLP-1 receptor agonist, a hormone mimic that helps regulate blood sugar and appetite. The label contraindicates use with a personal or family history of medullary thyroid carcinoma. It also rules out Multiple Endocrine Neoplasia syndrome type 2 or a serious product allergy.
"If pancreatitis is suspected, discontinue OZEMPIC and initiate appropriate management," the label states for "persistent or severe abdominal pain" with or without vomiting. For serious allergic reactions, the Medication Guide directs patients to stop the drug and "get medical help right away".
A legitimate U.S. pharmacy "Requires a doctor’s prescription" and "Has a licensed pharmacist to answer your questions" under FDA's BeSafeRx pharmacy guide. You can verify a pharmacy's license through its state board database. Confirming directly with the pharmacy also matters because some fake labels steal real pharmacy names.
"The agency recommends patients not use any injectable GLP-1 drug that arrives warm or with insufficient refrigeration," according to the FDA. FDA MedWatch Form 3500B records the "Lot number" and "Name(s) of the company that makes (or compounds) the product" for safety reports. At Promise, a licensed provider reviews every request, and not everyone qualifies.
What to Watch Next
Both September 2026 warning letters gave the sellers 15 business days after receipt to respond in writing. Because the public letters do not show delivery dates, no exact calendar deadline can be calculated.
The letters do not establish whether the sellers later corrected the cited violations. Both letters warn that further regulatory or legal action can occur without notice if violations are not corrected. Watch FDA's warning-letter database for updates and check official U.S. drug records before trusting any online listing.
